Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Application of NY-ESO-1-specific TCR Affinity Enhancing Specific T Cell Therapy (TAEST16001) in Solid Tumors Except Non Small Cell Lung Cancer,Including Liver Cancer,Gastric Cancer,Esophageal Cancer and so on

Trial Profile

Application of NY-ESO-1-specific TCR Affinity Enhancing Specific T Cell Therapy (TAEST16001) in Solid Tumors Except Non Small Cell Lung Cancer,Including Liver Cancer,Gastric Cancer,Esophageal Cancer and so on

Recruiting
Phase of Trial: Phase I

Latest Information Update: 08 Feb 2019

At a glance

  • Drugs TAEST 16001 (Primary) ; Cyclophosphamide; Fludarabine
  • Indications Advanced breast cancer; Bladder cancer; Bone cancer; Carcinoma; Gastric cancer; Liver cancer; Oesophageal cancer; Ovarian cancer; Prostate cancer; Soft tissue sarcoma; Thyroid cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 14 Jan 2019 Treatment change- interleukin-2 subcutaneous injection is removed from the treatment. Lymphodepleting regimen pretreatment with fludarabine and cyclophosphamide is added.
    • 14 Jan 2019 Planned End Date changed from 31 May 2019 to 31 Dec 2019.
    • 14 Jan 2019 Planned primary completion date changed from 31 May 2019 to 31 Dec 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top